The primary use of the Acetazolamide is to reduce nausea and dizziness associated with altitude sickness, but the drug is also used in treating certain types of eye probems and to lower the build-up body fluids in medical emergencies.
The US market for Acetazolamide Tablets is approximately USD 53 Million, the company said, quoting IMS.
“The approval, which was received in a short span of 11 months, demonstrates Company’s strategy of building a niche portfolio in regulated markets, having limited competition,” it said.
The product, to be launched immediately, will be marketed by Strides Pharma Inc. in the US Market.
Strides Shasun, headquartered in Bangalore, operates in regulated markets and emerging markets and also has a separate division supplying active pharmaceutical ingredients.